Pfizer Inc. $PFE Stock Holdings Raised by Huber Capital Management LLC

Huber Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 955,518 shares of the biopharmaceutical company’s stock after acquiring an additional 142,000 shares during the period. Pfizer accounts for about 3.5% of Huber Capital Management LLC’s portfolio, making the stock its 8th largest position. Huber Capital Management LLC’s holdings in Pfizer were worth $23,792,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. Triad Wealth Partners LLC raised its stake in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. raised its stake in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC raised its stake in Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC raised its stake in Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC raised its stake in Pfizer by 0.9% during the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 403 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Trading Up 0.1%

Shares of PFE opened at $26.19 on Friday. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a market cap of $149.26 billion, a P/E ratio of 19.99 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $26.43 and its 200-day simple moving average is $26.32.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PFE shares. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. HSBC upped their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. CICC Research initiated coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.